Bridging the Gap Between Epigenetic and Genetic in PAH

Quick Takes

  • Tet methylcytosine dioxygenase 2 (TET2), an epigenetic regulator that demethylates cytosine, is mutated in both idiopathic pulmonary arterial hypertension (PAH) and associated PAH.
  • TET2 expression is ubiquitously decreased in peripheral blood cells of paitents with both idiopathic and associated PAH.
  • TET2 depletion creates a pro-inflammatory phenotype in patients with PAH and mice with a deficiency of TET2.

The Genetic Basis for PAH
PAH is a lethal vasculopathy characterized by increased mean pulmonary arterial pressure above 20 mmHg and pulmonary vascular resistance > 3 Wood units1 in the absence of left heart disease, chronic lung disease and hypoxia, or thromboembolic disease. The etiology of the disease is heterogenous and remains poorly understood, although it is characterized by increased inflammation, fibrosis and impaired angiogenesis, and disordered mitochondrial metabolism and dynamics. Approximately 7% of PAH cases are familial. By far the most common gene mutations in patients with PAH are heterozygous germline mutations in the bone morphogenetic protein receptor 2 gene, BMPR2, although 16 other PAH genes have been identified.2 Gene mutations, including mutations of the genes ACVRL1, ENG, CAV1, KCNK3, and EIF2AK4, occur in under 15% of patients with idiopathic PAH and are rare in PAH associated with connective tissue diseases (associated PAH). In addition to genetic causes of PAH, epigenetic dysregulation of gene expression has emerged as a critical player of PAH development and progression.

PAH and Epigenetics
Epigenetics is defined as a change in gene expression that occurs without alteration in the DNA sequence and underlies most gene-environment interactions. There are three major mechanisms by which epigenetic regulation changes gene expression, including histone modifications (e.g., acetylation and methylation), non-coding RNA (microRNA and long non-coding RNA), and DNA methylation.3 DNA methylation is a mechanism by which cells or organisms adapt gene expression in response to their environment, including pathological or physiologic stressors (such as inflammation), metabolic changes, and/or hypoxia. DNA methylation is mediated by the addition of methyl groups on DNA nucleotides, mainly in CpG islands, which are regions of the DNA rich in cytosine and guanine. DNA methylation in promoter and enhancer regions impairs access to transcription factors and other regulatory proteins and in general impairs gene expression. DNA methylation is a dynamic process that reflects the balance between the activity of DNA methyltransferases (a family of enzymes that add methyl groups in CpG islands) and TET enzymes, which remove these methyl groups.

PAH and DNA Methylation
Our group and others have identified an important contribution of DNA methylation in PAH, relevant to the development of both pulmonary vascular disease and right ventricular (RV) failure. In experimental models of PAH, we reported that DNA hypermethylation decreases superoxide dismutase 2 gene expression leading to normoxic activation of hypoxia-inducible transcription factor-1alpha, through a redox mechanism.4 The resulting pseudohypoxic environment leads to metabolic dysfunction and results in smooth muscle cell proliferation and apoptosis resistance. Conversely, treatment with 5-azacytidine, a DNA methyltransferase inhibitor, leads to high expression of superoxide dismutase 2 and reduces proliferation of smooth muscle cells. The increased DNA methyltransferase activity relates to tissue-specific upregulation of several DNA methyltransferase isoforms in pulmonary vascular cells. Supporting this observation, we demonstrated that RV fibroblasts extracted from a preclinical model of PAH with RV failure are hyper-methylated, and we have demonstrated that this leads to their hyperproliferative and pro-fibrotic phenotype in vitro.5 We also reported that increased DNA methylation is associated with angiogenic defects observed in decompensated RV from patients with PAH.6 In vitro, hydralazine (an antihypertensive agent used to treat heart failure that is also a hypomethylating agent) restores the angiogenic potential of endothelial cells isolated from the decompensated RV in PAH. This is a reminder that epigenetic abnormalities may be particularly amenable to therapy because genes that are silenced by methylation can be reactivated by demethylation.

Genetic and Epigenetic
Our recent work suggests that the separation of genetic and epigenetic mechanisms is arbitrary in PAH.7 Both mutations and impaired epigenetic regulation of a single pathway can occur in patients with PAH. Using the largest PAH patient cohort that exists to date worldwide (the National Biological Sample and Data Repository for Pulmonary Arterial Hypertension, or PAH Biobank; 2,572 cases), our team described a genetic association of germline and somatic mutations of the TET2 gene in patients with idiopathic and associated PAH. TET2 mutation occurs in 0.39% of the patients with PAH, with 75% of the mutations being germline and 25% of the mutations being somatic. There was a significant increase in the expression of loss-of-function variants in TET2 in patients with PAH compared with control subjects. Moreover, TET2 mutation is associated with sixfold increase in the relative risk to develop PAH compared with the Genome Aggregation Database control group. Patients carrying a TET2 mutation lacked a positive response to acute vasodilator challenge, which is a marker of poor prognosis. Among the TET family of genes, TET2 is most critical to the DNA demethylation process.8 In an independent cohort of 140 patients within this study, we reported that circulating TET2 expression was decreased in >86% of patients with PAH (both idiopathic PAH and PAH associated with connective tissue disease) compared to healthy control subjects. Thus, although the gene mutation was rare, the epigenetic downregulation of the TET2 expression was common. Finally, to confirm the biologic plausibility of TET2 mutations as a cause of PAH, we generated a conditional TET2 knockout mouse and demonstrated that it spontaneously developed PAH as it aged, characterized by increased mean pulmonary arterial pressure, adverse pulmonary vascular remodeling, and decreased lung perfusion.

Our early preliminary and unpublished data suggest that PAH is also associated with an increased burden of rare, predicted damaging mutation in a gene, DNA methyltransferase 3A (DNMT3A). DNMT3A is also involved in the regulation of DNA methylation. A sub-cohort analysis reveals that DNMT3A mutation might be preferentially associated with PAH associated with connective tissue disease rather than idiopathic PAH, although this reflects research in progress in our group. As with TET2, we reported a ubiquitous decrease of DNMT3A expression in the blood of both patients with idiopathic PAH and patients with PAH associated with connective tissue disease compared to healthy controls, a reminder that epigenetic regulation of an epigenetic gene regulator is much more common than a mutation in the same gene, though both are associated with increased risk of developing PAH.

A Step Toward Personalized Medicine
Aside from being a critical factor involved in the regulation of DNA methylation processes, TET2 also contributes to the regulation of inflammation.9 Several studies demonstrated that TET2 depletion leads to a pro-inflammatory phenotype.10 Corroborating this observation, we reported that TET2 mutation is associated with increased levels of pro-inflammatory cytokines (e.g., interleukin-1-beta [IL-1b]) in the blood of patients with PAH compared to both non-mutated and healthy controls. We also observed an increased expression of inflammatory markers in the blood of TET2 mutated mice, with IL-1b being the most over-expressed cytokine (compared to non-mutated mice). Thus, our data demonstrated that TET2 mutation/depletion is associated with increased inflammation in both mice and patients with PAH. CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study),11 which investigated the effect of a monoclonal antibody targeting IL-1b (canakinumab) in cardiovascular diseases, identified the presence of clonal hematopoiesis of indeterminate potential (involving TET2 mutation) in 8.8% of the cohort. Patients with a somatic mutations in TET2 showed a greater magnitude of risk for major adverse cardiovascular events; however, they also displayed an improved therapeutic response to canakinumab.12 Similarly, we reported that the murine version of canakinumab prevents PAH development (decreased mean pulmonary arterial pressure and adverse pulmonary vascular remodeling) in our TET2 mutated mice.7 Thus, we speculate that TET2 mutation might be a useful predictor of a positive response to anti-inflammatory therapy in PAH, although confirmation of this hypothesis would be required.

Clonal Hematopoiesis of Indeterminate Potential and PAH
Clonal hematopoiesis of indeterminate potential is a common, age-related phenomenon in which somatic mutations of several genes, including TET2 and DNMT3A, in blood cell progenitors contribute to the formation of genetically distinct subpopulations of clonally abnormal blood cells.13 Besides increasing the risk of hematologic cancer, clonal hematopoiesis of indeterminate potential is associated with an increased risk of coronary heart disease, myocardial infarction, and death.14-16 Although our published7 and preliminary data (increased burden of TET2 and DNMT3A somatic and germline deleterious mutation in PAH blood) suggest a potential association between clonal hematopoiesis of indeterminate potential and PAH, further studies are underway to confirm this speculation.

In conclusion, our international team of clinical PAH specialists Dr. Archer and Dr. Hassoun, hematologist Dr. Rauh, biobanking expert Dr. Pauciulo, physiologist Dr. Tian, molecular biologist Dr. Lima, and geneticists Dr. Chung and Dr. Nichols used a translational approach to demonstrate the association between deleterious mutations in genes involved in the regulation of DNA methylation and PAH development. We identified novel concepts regarding the potential genetic control of epigenetics dysfunction in PAH that suggest a contribution of clonal hematopoiesis of indeterminate potential in the development of PAH and a related role for anti-inflammatory therapies. Further studies are needed to understand the broader role of clonal hematopoiesis of indeterminate potential in PAH.


  1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
  2. Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:1801899.
  3. Cheng X, Wang Y, Du L. Epigenetic Modulation in the Initiation and Progression of Pulmonary Hypertension. Hypertension 2019;74:733-9.
  4. Archer SL, Marsboom G, Kim GH, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121:2661-71.
  5. Tian L, Wu D, Dasgupta A, et al. Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis. Circ Res 2020;126:1723-45.
  6. Potus F, Ruffenach G, Dahou A, et al. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation 2015;132:932-43.
  7. Potus F, Pauciulo MW, Cook EK, et al. Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation 2020;141:1986-2000.
  8. Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 2016;30:733-50.
  9. Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol 2017;55:56-70.e13.
  10. Cai Z, Kotzin JJ, Ramdas B, et al. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. Cell Stem Cell 2018;23:833-849.e5.
  11. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017;377:1119-31.
  12. Svensson EC, Madar A, Campbell CD, et al. Abstract 15111: TET2-Driven Clonal Hematopoiesis Predicts Enhanced Response to Canakinumab in the CANTOS Trial: An Exploratory Analysis. Circulation 2018;138:A15111.
  13. Ferrone CK, Blydt-Hansen M, Rauh MJ. Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. Int J Mol Sci 2020;21:626.
  14. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017;355:842-7.
  15. Rauch PJ, Silver AJ, Gopakumar J, et al. Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice. Blood 2018;132:745.
  16. Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol 2020;17:137-44.

Clinical Topics: Heart Failure and Cardiomyopathies, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Novel Agents, Statins, Heart Failure and Cardiac Biomarkers, Pulmonary Hypertension, Hypertension

Keywords: Hypertension, Hypertension, Pulmonary, Epigenesis, Genetic, Inflammation, CpG Islands, Antihypertensive Agents, Cytosine, DNA Methylation, RNA, Long Noncoding, Bone Morphogenetic Protein Receptors, Type II, Transcription Factors, Histone Code, Azacitidine, MicroRNAs, Down-Regulation, Interleukin-1beta, Cytokines, Cardiovascular Diseases, Specialization, Arterial Pressure, Biological Specimen Banks, Antibodies, Monoclonal, Hematopoiesis

< Back to Listings